---

Pancreatic Enzyme Replacement Therapy: Supply Chains

Answer

The Department is aware of ongoing intermittent supply issues with pancreatic enzyme replacement therapy (PERT) and is continuing to work with all suppliers of PERT to help resolve the supply issues in the short and longer term. This includes asking that they expedite deliveries, source stock from other markets, and increase production. Through these discussions we have managed to secure additional volumes for 2025 for the United Kingdom. The Department has also reached out to specialist importers who have sourced unlicensed stock to assist in covering the remaining gap in the market.

In the longer term, the Department has had interest from non-UK suppliers of PERT wishing to bring their products to the UK and, along with colleagues in the Medicine and Healthcare products Regulatory Agency, we are working with these potential suppliers, and if authorised, these products could further diversify and strengthen the market.

The Department has issued management advice to healthcare professionals which directs clinicians to unlicensed imports when licensed stock is unavailable, and which includes actions for integrated care boards to ensure local mitigation plans are implemented. The Department, in collaboration with NHS England, has created a public facing page to include the latest update on PERT availability and easily accessible prescribing advice for clinicians.

The Department will continue to work closely with the manufacturers to resolve the issues as soon as possible, to ensure patients have continuous access to medicines.

Secondary information

Type

Written question

Reference

69659

Session

2024-26

Subjects

Shortages Supply chains Pancreatic enzyme replacement therapy

Link

View this Written question on www.parliament.uk